[{"data":1,"prerenderedAt":204},["ShallowReactive",2],{"drug-vericiguat":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":78,"warnings":88,"renal":96,"monitoring":97,"interactions":98,"review":107,"examples":110,"atc":116,"iran":118,"usApproval":138,"links":144,"populations":160},"vericiguat",1,{"fa":7,"en":8},"وریسیگوات","Vericiguat","cardiovascular",{"fa":11,"en":12},"محرک گوانیلات سیکلاز محلول","Soluble guanylate cyclase stimulator",[14],{"name":15,"market":16},"Verquvo","US",[18,19,7],"verquvo","ورکوو",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-2-5","tablet","oral","2.5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},2.5,"mg",false,[16],[32],{"source":33,"section":34},"fda-verquvo","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-5","5 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},5,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-10","10 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},10,[16],[50],{"source":33,"section":34},[52],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":28,"dose":63,"refs":66,"notes":69},"hfref","heart-failure",{"fa":56,"en":57},"نارسایی قلبی با EF زیر ۴۵٪ پس از بدتر شدن — شروع ۵ mg، هر ۲ هفته دو برابر تا ۱۰ mg","HFrEF (EF \u003C45%) after worsening — start 5 mg, double every 2 weeks to 10 mg",{"minAge":59},{"value":60,"unit":61},18,"year","titration",{"dividedDoses":5,"titration":64},{"start":39,"incrementEveryDays":65,"max":47},14,[67],{"source":33,"section":68},"2.1",[70],{"text":71,"refs":74},{"fa":72,"en":73},"با غذا. در خطر افت فشار علامت‌دار: شروع ۲٫۵ mg. زن در سن باروری: تست بارداری پیش از شروع.","With food. At risk of symptomatic hypotension: start 2.5 mg. Females of reproductive potential: pregnancy test before starting.",[75,76],{"source":33,"section":68},{"source":33,"section":77},"2.2",[79],{"id":80,"severity":81,"text":82,"refs":85},"ci","block",{"fa":83,"en":84},"مصرف همزمان سایر محرک‌های گوانیلات سیکلاز محلول (ریوسیگوات)؛ بارداری.","Concomitant other soluble guanylate cyclase stimulators (e.g. riociguat); pregnancy.",[86],{"source":33,"section":87},"4",[89],{"text":90,"refs":93},{"fa":91,"en":92},"هشدار جعبه‌ای: سمیت جنینی — رد بارداری پیش از شروع و پیشگیری مؤثر تا ۱ ماه پس از قطع.","Boxed warning: embryo-fetal toxicity — exclude pregnancy before starting and use effective contraception until 1 month after stopping.",[94],{"source":33,"section":95},"Boxed Warning",[],[],[99],{"with":100,"text":101,"refs":104},"pde5",{"fa":102,"en":103},"مهارکننده‌های PDE5: توصیه نمی‌شود (افت فشار).","PDE5 inhibitors: not recommended (hypotension).",[105],{"source":33,"section":106},"7",{"status":108,"reviewer":109,"date":109},"unverified",null,[111],{"regimen":53,"formulation":36,"input":112,"expect":115},{"ageYears":113,"weightKg":114},70,75,{"perDose":39,"tabletsPerDoseRounded":5},[117],"C01DX22",{"status":119,"forms":120,"refs":133},"registered",[121,125,129],{"code":122,"en":123,"fa":124},"53611","VERICIGUAT 2.5 mg TABLET","قرص وریسیگوات 2.5 میلی گرم",{"code":126,"en":127,"fa":128},"53612","VERICIGUAT 5 mg TABLET","قرص وریسیگوات 5 میلی گرم",{"code":130,"en":131,"fa":132},"53613","VERICIGUAT 10 mg TABLET","قرص وریسیگوات 10 میلی گرم",[134],{"source":135,"section":136,"url":137},"darooyab-generic","G-5577\u002FVericiguat","https:\u002F\u002Fwww.darooyab.ir\u002FG-5577\u002FVericiguat",{"kind":139,"refs":140,"id":143},"NDA",[141],{"source":33,"section":142},"SPL approval \u002F marketing category","NDA214377",[145,148,152,155,158],{"kind":146,"url":147,"label":143},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=214377",{"kind":149,"url":150,"label":151},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=17056d73-1b1b-4bf2-9c07-b7a9367f0d6d","FDA Verquvo",{"kind":153,"url":154,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa621014.html",{"kind":156,"url":157,"label":117},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C01DX22",{"kind":159,"url":137,"label":8},"darooyab",{"pregnancy":161,"lactation":169,"pediatric":178,"geriatric":187,"reproductive":196},{"level":162,"text":163,"quote":166,"refs":167},"contraindicated",{"fa":164,"en":165},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","VERQUVO is contraindicated in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ].",[168],{"source":33,"section":87},{"level":170,"text":171,"quote":174,"refs":175},"avoid",{"fa":172,"en":173},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.",[176],{"source":33,"section":177},"8.2",{"level":179,"text":180,"quote":183,"refs":184},"caution",{"fa":181,"en":182},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of VERQUVO have not been established in pediatric patients.",[185],{"source":33,"section":186},"8.4",{"level":188,"text":189,"quote":192,"refs":193},"ok",{"fa":190,"en":191},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dosage adjustment of VERQUVO is required in geriatric patients.",[194],{"source":33,"section":195},"8.5",{"level":179,"text":197,"quote":200,"refs":201},{"fa":198,"en":199},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females VERQUVO may cause fetal harm when administered to a pregnant woman.",[202],{"source":33,"section":203},"8.3",1792156199471]